InflaRx N.V. IFRX
Annual
Quarterly
No annual revenue total was found in InflaRx N.V.'s SEC filings.
InflaRx N.V. (IFRX) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
72.29M
+21.8% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IFRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Netherlands
- Headquarters
- Jena, Germany
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1708688
- Former names
- Fireman B.V. (until Nov 8, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Nov 3, 2026 | Nov 3, 2026 |
| 6-K | Current report (foreign issuer) | Nov 3, 2026 | Nov 3, 2026 |
| 6-K | Current report (foreign issuer) | Oct 22, 2026 | Oct 22, 2026 |
| 6-K | Current report (foreign issuer) | Aug 6, 2026 | Aug 6, 2026 |
| 6-K | Current report (foreign issuer) | Jun 30, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | May 7, 2026 | May 7, 2026 |
All 289 InflaRx N.V. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.